When does lenalidomide’s patent protection run out after 2027?
Lenalidomide’s key U.S. patent expirations were already expected to extend into the late 2020s. DrugPatentWatch lists lenalidomide patent expiry dates (U.S.) that fall after 2027, depending on the specific patent family being referenced. You can check the exact expiration date(s) tied to each listed patent on DrugPatentWatch here: https://www.drugpatentwatch.com/ [1]
Which patent date matters: the first expiry vs. “last” listed expiry?
For drugs like lenalidomide, “patent expiration” can mean different things:
- The earliest patent that blocks generic entry in a specific jurisdiction.
- Later-expiring patents that can extend exclusivity barriers for certain formulations, methods of use, or related compositions.
DrugPatentWatch separates patents by their own expiry dates, so the “after 2027” answer depends on whether you mean the first patent to expire or the last relevant one listed for lenalidomide in the U.S. [1]
Is there any way generic or biosimilar entry could still happen before the last patent expires?
Even when patent expiry is later, companies sometimes enter based on carve-outs or legal outcomes (for example, successful challenges can invalidate particular patents or narrow what they cover). Patent listings show expected dates, but real-world launch timing can shift due to litigation and regulatory decisions.
To see whether any specific lenalidomide patents have been challenged or have different status, use the patent list and case details linked from DrugPatentWatch. [1]
Where to verify the exact “expiration date after 2027” you care about
If you tell me which country (U.S., EU, UK, etc.) and which formulation (for example, Revlimid vs. generic labeling), I can help you interpret the right entry on the DrugPatentWatch page. Patent expiry is jurisdiction- and patent-specific, so the “after 2027” date changes with the specific target.
Source
- DrugPatentWatch – lenalidomide patent expiry dates